925 related articles for article (PubMed ID: 28838273)
61. Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis.
Kim ES; Kim SK; Park DI; Kim HJ; Lee YJ; Koo JS; Kim ES; Yoon H; Lee JH; Kim JW; Shin SJ; Kim HW; Kim HS; Park YS; Kim YS; Kim TO; Lee J; Choi CH; Han DS; Chun J; Kim HS;
J Clin Gastroenterol; 2023 Jul; 57(6):601-609. PubMed ID: 35470308
[TBL] [Abstract][Full Text] [Related]
62. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.
Bálint A; Rutka M; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Szepes Z; Nagy F; Palatka K; Lovas S; Végh Z; Kürti Z; Csontos Á; Miheller P; Nyári T; Bor R; Milassin Á; Fábián A; Szántó K; Lakatos PL; Molnár T; Farkas K
Expert Opin Biol Ther; 2018 Nov; 18(11):1181-1187. PubMed ID: 30277084
[TBL] [Abstract][Full Text] [Related]
63. Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab.
Fischer S; Cohnen S; Klenske E; Schmitt H; Vitali F; Hirschmann S; Ramming A; Zundler S; Rath T; Krebs S; Dörje F; Uter W; Nagore D; Meyer S; Neurath MF; Atreya R
Therap Adv Gastroenterol; 2021; 14():1756284820982802. PubMed ID: 33505519
[TBL] [Abstract][Full Text] [Related]
64. The switch to biosimilar infliximab as a cause of treatment cessation in 3 paediatric patients with Crohn's disease.
Vande Velde S
Acta Gastroenterol Belg; 2020; 83(4):657-659. PubMed ID: 33321025
[TBL] [Abstract][Full Text] [Related]
65. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
Jung YS; Park DI; Kim YH; Lee JH; Seo PJ; Cheon JH; Kang HW; Kim JW
J Gastroenterol Hepatol; 2015 Dec; 30(12):1705-12. PubMed ID: 25974251
[TBL] [Abstract][Full Text] [Related]
66. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Graziani MG; Lorenzetti R; Luzza F; Paese P; Penna A; Pica R; Pranzo G; Rodinò S; Scarcelli A; Zampaletta C; Brozzi L; Cicerone C; Cocco A; De' Angelis G; Donnarumma L; Fiorella S; Iannelli C; Larussa T; Le Grazie M; Luppino I; Meucci C; FaggianI R; Pagnini C; Perazzo P; Rodriguez-Castro KI; Sacco R; Sebkova L; Serio M; De Monti A; Picchio M; Napolitano D; Schiavoni E; Turchini L; Scaldaferri F; Pugliese D; Guidi L; Laterza L; Privitera G; Pizzoferrato M; Lopetuso LR; Armuzzi A; Elisei W; Maconi G; Papa A
Expert Opin Biol Ther; 2022 Feb; 22(2):313-320. PubMed ID: 34904510
[TBL] [Abstract][Full Text] [Related]
67. Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort.
Chanchlani N; Mortier K; Williams LJ; Muhammed R; Auth MKH; Cosgrove M; Fagbemi A; Fell J; Chong S; Zamvar V; Hyer W; Bisset WM; Morris MA; Rodrigues A; Mitton SG; Bunn S; Beattie RM; Willmott A; Wilson DC; Russell RK
J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):513-519. PubMed ID: 29697550
[TBL] [Abstract][Full Text] [Related]
68. Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease.
Bernard EJ; Fedorak RN; Jairath V
Dig Dis Sci; 2020 Aug; 65(8):2354-2372. PubMed ID: 31970610
[TBL] [Abstract][Full Text] [Related]
69. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
[TBL] [Abstract][Full Text] [Related]
70. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).
Abraham B; Eksteen B; Nedd K; Kale H; Patel D; Stephens J; Shelbaya A; Chambers R; Soonasra A
Adv Ther; 2022 May; 39(5):2109-2127. PubMed ID: 35296993
[TBL] [Abstract][Full Text] [Related]
71. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb.
Bhat S; Altajar S; Shankar D; Zahorian T; Robert R; Qazi T; Shah B; Farraye FA
J Manag Care Spec Pharm; 2020 Apr; 26(4):410-416. PubMed ID: 32223602
[TBL] [Abstract][Full Text] [Related]
72. Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease.
Kim ES; Choi S; Choe BH; Park S; Lee YJ; Sohn SJ; Kim SC; Kang KS; Lee K; Shim JO; Kim YB; Hong SJ; Lee YM; Kim HJ; Choi SY; Kim JY; Lee Y; Park JS; Kim JY; Yi DY; Lee JH; Choi KH; Jang HJ; Jeong IS; Kang B
Front Immunol; 2024; 15():1284181. PubMed ID: 38455036
[TBL] [Abstract][Full Text] [Related]
73. Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD).
Bokemeyer B; Hlavaty T; Allez M; Selema P; Moosavi S; Cadatal MJ; Fowler H; Mueller M; Liau KF; Gisbert JP
Expert Opin Biol Ther; 2023; 23(8):791-800. PubMed ID: 37038897
[TBL] [Abstract][Full Text] [Related]
74. Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study.
Hellström PM; Gemmen E; Ward HA; Koo H; Faccin F; Xue Z; Malmborg P
Scand J Gastroenterol; 2022 Dec; 57(12):1435-1442. PubMed ID: 35833832
[TBL] [Abstract][Full Text] [Related]
75. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
Luber RP; O'Neill R; Singh S; Sharma E; Cunningham G; Honap S; Meade S; Ray S; Anderson SH; Mawdsley J; Sanderson JD; Samaan MA; Arkir Z; Irving PM
Aliment Pharmacol Ther; 2021 Sep; 54(5):678-688. PubMed ID: 34223654
[TBL] [Abstract][Full Text] [Related]
76. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
Takeuchi T; Nishikawa K; Yamada F; Morita A; Ohtsuki M; Suzuki Y; Watanabe M; Yamanaka H; Hibi T
Drug Saf; 2023 Oct; 46(10):991-1005. PubMed ID: 37700154
[TBL] [Abstract][Full Text] [Related]
77. Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study.
Ho SL; Niu F; Pola S; Velayos FS; Ning X; Hui RL
BioDrugs; 2020 Jun; 34(3):395-404. PubMed ID: 32103457
[TBL] [Abstract][Full Text] [Related]
78. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease.
Ebada MA; Elmatboly AM; Ali AS; Ibrahim AM; Fayed N; Faisal AF; Alkanj S
Int J Colorectal Dis; 2019 Oct; 34(10):1633-1652. PubMed ID: 31492986
[TBL] [Abstract][Full Text] [Related]
79. CT-P13: design, development, and place in therapy.
Gabbani T; Deiana S; Annese V
Drug Des Devel Ther; 2017; 11():1653-1661. PubMed ID: 28652703
[TBL] [Abstract][Full Text] [Related]
80. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K
Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]